RxDoctor Payments Data

Heidi Anderson, MD

Dermatology · Sarasota, FLNPI 1386687077

Payments from drug & device makers

$8,864in general payments, 2019–2025

Across 436 payments — averaging $20.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Sun Pharmaceutical Industries Inc.$927
  • Novartis$780
  • Sanofi$588
  • Johnson & Johnson$545
  • Lilly USA, LLC$400
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$8,864100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,864 in reported general payments places this provider in the 70th percentile of 1,147 dermatology providers in Florida.

See all dermatology providers in Florida

Medicare billing

Part B allowed, 2024
$418,879
Medicare patients
1,785
Services billed
6,087

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast22$102,584
Fluorouracil111$6,325
Naftifine Hcl11$4,106
Clindamycin Phosphate71$2,359
Fluocinonide92$2,148
Betamethasone Dipropionate57$1,931
ValacyclovirValacyclovir Hcl54$1,396
Clobetasol Propionate30$1,388
Gentamicin Sulfate36$1,239
Triamcinolone Acetonide120$1,177
Doxycycline Hyclate67$1,068
Metronidazole19$958
Nystatin85$916
Ketoconazole71$903
Imiquimod45$715

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$340$102,58422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,147 dermatology providers in Florida.

Other dermatology in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →